Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1017850 | 0.80 | BRAF (0.48) | MAPK14MAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL1016030 | 0.79 | MAPK14 (0.53) | MAPK14MAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL2478461 | 0.79 | MAPK14 (0.54) | MAPK14MAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL14519385 | 0.78 | MKNK1 (0.51) | MAPK14MAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL19972125 | 0.78 | MKNK1 (0.51) | MAPK14MAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL1016280 | 0.77 | LRRK2 (0.46) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL1015963 | 0.77 | DYRK1A (0.51) | MAPK14MAPK11BRAFCDC7LRRK2 | |
| SCHEMBL19926114 | 0.76 | CDK4 (0.53) | MAPK14MAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL20837140 | 0.75 | MKNK1 (0.47) | MKNK1MKNK2NPC1RAB9AGAA | |
| SCHEMBL8382254 | 0.75 | NPC1 (0.62) | MAPK14MAPK13RAF1MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102083835-A | Bridged, bicyclic heterocyclic or spiro bicyclic heterocyclic derivatives of pyrazolo[1,5-A]pyrimidines, methods for preparation and uses thereof | WYETH CORP | 2011-06-01 | — | — | CN | disclosed |
| EP-2271649-A1 | BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | Wyeth LLC (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-2203453-A1 | PYRAZOLO[5, 1-C] [1,2,4]TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009108838-A1 | BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | WYETH (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009108827-A1 | FUSED TRICYCLIC PYRAZOLO[1, 5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | WYETH (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009039387-A1 | PYRAZOLO[5, 1-C] [1,2,4] TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | WYETH (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082354-A1 | PYRAZOLO[5, 1-C] [1,2,4] TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | WYETH (US) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082354-A1 | PYRAZOLO[5, 1-C] [1,2,4] TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | RAF1, BRAF, ARAF | MAPK14 242/4885MAPK13 186/4885RAF1 1/4885 |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | BRAF, RAF1, ARAF | MAPK14 70/4885MAPK13 85/4885RAF1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.